Treatment of anorexia with megestrol acetate.
Anorexia and involuntary weight loss are prevalent problems in oncology and AIDS patients. Cytokines are suspected but not proven causes of cachexia. Megestrol acetate has been found to increase appetite, food intake, and weight in randomized, placebo-controlled trials in patients with advanced malignancies and in patients with AIDS. This hormone derivative probably has both central nervous system and peripheral metabolic effects. No significant effect on survival has been demonstrated in these trials. The optimal dose for appetite enhancement is unknown; we have chosen 320 mg/d as our initial dose. Megestrol acetate is usually well tolerated, and it may be helpful in the symptomatic and palliative therapy of patients with anorexia and weight loss.
Tchekmedyian
N S
NS
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000855:Anorexia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D019290:Megestrol Acetate; D009369:Neoplasms / Q000150:complications*
D008535:Megestrol; D019290:Megestrol Acetate